Temporal and subcellular distributions of Cy5.5-labeled hyaluronic acid nanoparticles in mouse organs during 28 days as a drug carrier.
10.14405/kjvr.2017.57.4.215
- Author:
Chunmei LIN
1
;
Saet Byeol KIM
;
Jung Min YON
;
Seul Gi PARK
;
Lee Wha GWON
;
Jong Geol LEE
;
In Jeoung BAEK
;
Beom Jun LEE
;
Young Won YUN
;
Sang Yoon NAM
Author Information
1. College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130-118, China.
- Publication Type:Original Article
- Keywords:
drug delivery systems;
hyaluronic acid;
nanoparticles;
pharmacokinetics;
subcellular localization
- MeSH:
Animals;
Cytoplasm;
Drug Carriers*;
Drug Delivery Systems;
Fluorescence;
Hyaluronic Acid*;
Kidney;
Kupffer Cells;
Liver;
Macrophages;
Mice*;
Nanoparticles*;
Pharmacokinetics;
Spleen
- From:Korean Journal of Veterinary Research
2017;57(4):215-222
- CountryRepublic of Korea
- Language:English
-
Abstract:
Temporal and subcellular distributions of hyaluronic acid (HA) as a degradable nanoparticle (NP) in animals were investigated to determine if HA-NP could be utilized as an appropriate drug delivery system. After mice were intravenously injected with 5 mg/kg of Cy5.5-labeled HA-NP sized 350–400 nm or larger HA-polymers, the fluorescence intensity was measured in all homogenized organs from 0.5 h to 28 days. HA-NP was greatly detected in spleen, liver and kidney until day 28, while it was maintained at low levels in other organs. HA-polymer was observed at low levels in all organs. HA-NP quantities in spleen and liver were reduced until day 3, but increased sharply between days 3 and 7, then decreased again, while their HA-polymers were maintained at low levels until day 28. In kidneys, both HA-NP and HA-polymer showed high levels after 0.5 h of administration, but steadily decreased until day 28. According to ultrastructural analyses, HA-NP was engulfed in Kupffer cells of liver and macrophages of spleen and kidney at day 1 and was accumulated in the cytoplasm of kidney tubular cells at day 7. Overall, these findings suggest that HA-NP could be considered a desirable drug carrier in the liver, kidney, or spleen.
